New drug trial offers hope for untreated lymphoma patients
NCT ID NCT06569680
Summary
This study is testing whether the medication mosunetuzumab can help people with newly diagnosed extranodal marginal zone lymphoma (EMZL) who haven't received any cancer treatment yet. The trial will enroll 35 adults with stage I-IV disease to see how well the drug works at eliminating or shrinking their cancer and how safe it is. Researchers will track how many patients achieve complete remission and monitor side effects over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.